Table 4 Multivariate analysis of mortality and DMFP risk factors and SLC39A6/GATA3.
Overall survival | Distant metastasis-free probability | |||
|---|---|---|---|---|
Hazard ratio (95% confidence interval) | p-value | Hazard ratio (95% confidence interval) | p-value | |
SLC39A6/GATA3: Group 2 vs. Group 1 | 1.557 (0.7914 – 3.061) | 0.2000 | 1.208 (0.621 – 2.347) | 0.5800 |
SLC39A6/GATA3: Group 3 vs. Group 1 | 1.675 (0.9739 – 2.882) | 0.0620 | 1.207 (0.715 – 2.038) | 0.4800 |
Age (decade) | 0.678 (0.4722 – 0.973) | 0.0350 | 0.720 (0.513 – 1.011) | 0.0580 |
Tumor diameter (cm) | 1.022 (0.9964 – 1.048) | 0.0940 | 1.033 (1.009 – 1.058) | 0.0067 |
Lymph node status (positive node) | 1.019 (0.8396 – 1.237) | 0.8500 | 1.054 (0.894 – 1.241) | 0.5300 |
Tumor grade: Poorly diff. vs. Intermediate | 1.403 (0.7994 – 2.463) | 0.2400 | 1.117 (0.657 – 1.901) | 0.6800 |
Tumor grade: Well diff. vs. Intermediate | 0.222 (0.0769 – 0.643) | 0.0055 | 0.381 (0.180 – 0.806) | 0.0120 |
Vascular invasion: 1–3 vessels vs. ≥ 4 vessels | 0.678 (0.2352 – 1.956) | 0.4700 | 0.577 (0.217 – 1.532) | 0.2700 |
Vascular invasion: 0 vessels vs. ≥ 4 vessels | 0.638 (0.1456 – 2.794) | 0.5500 | 0.597 (0.157 – 2.263) | 0.4500 |
Mastectomy vs. breast conserving therapy | 1.078 (0.6682 – 1.738) | 0.7600 | 1.165 (0.733 – 1.851) | 0.5200 |
Chemo and hormonal therapy v. no adjuvant therapy | 0.718 (0.3291 – 1.567) | 0.4100 | 0.496 (0.245 – 1.005) | 0.0510 |